Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

Rhea-AI Summary

Jade Biosciences (NASDAQ: JBIO), a biotechnology company specializing in autoimmune disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference from June 3-5, 2025, in New York. CEO Tom Frohlich will deliver a company presentation on June 4 at 4:55-5:25 p.m. ET. The management team will also conduct investor meetings during the event.

The presentation will be accessible to investors and the public through the Investors and Media section of JadeBiosciences.com, with the recording remaining available for 90 days afterward.

News Market Reaction – JBIO

+0.35%

+0.35% Session move

In the trading session that priced this news, JBIO gained 0.35%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference, June 3-5, 2025, in New York.  

Tom Frohlich, Chief Executive Officer of Jade, will deliver a company presentation on Wednesday, June 4 at 4:55-5:25 p.m. ET. Members of the management team will also host investor meetings during the conference.

Investors and the general public are invited to listen to the session by visiting the Investors and Media page on JadeBiosciences.com. An archived edition will be available following its conclusion for 90 days.

About Jade Biosciences, Inc.

Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE-001, targets the cytokine APRIL for immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade’s pipeline also includes two undisclosed antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.

Jade Biosciences Contacts

Media Contact
Priyanka Shah
Media@JadeBiosciences.com
908-447-6134

Investor Contact
IR@JadeBiosciences.com  

FAQ

When is Jade Biosciences (JBIO) presenting at the 2025 Jefferies Healthcare Conference?

Jade Biosciences (JBIO) will present on Wednesday, June 4, 2025, from 4:55-5:25 p.m. ET at the Jefferies Global Healthcare Conference in New York.

Who will be presenting for Jade Biosciences at the 2025 Jefferies Conference?

Tom Frohlich, Chief Executive Officer of Jade Biosciences, will deliver the company presentation.

How can investors access Jade Biosciences' (JBIO) Jefferies Conference presentation?

Investors can access the presentation through the Investors and Media page on JadeBiosciences.com. The recording will be available for 90 days after the event.

What is Jade Biosciences' (JBIO) main business focus?

Jade Biosciences is a biotechnology company focused on developing best-in-class therapies for autoimmune diseases.